Initially, up to 30 DeepView devices will be deployed in burn centers and emergency rooms for Spectral MD’s clinical validation study. The equipment is expected to be used for routine care after commercial clearance by the Food and Drug Administration.The BARDA contract also includes options valued at $95 million to expand the product rollout beyond the 30 devices.
“This is a significant contract award that enables us to accelerate the late-stage clinical development and commercialization of our DeepView system,” said CEO Wensheng Fan in a statement. “For the first time, there will be an accurate and objective solution in burn wound healing assessment to guide treatment.”Advertisement
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: